Ascendis Pharma A/S (NASDAQ:ASND) Position Lessened by Maven Securities LTD

Maven Securities LTD reduced its holdings in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 80.0% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 10,000 shares of the biotechnology company's stock after selling 40,000 shares during the quarter. Maven Securities LTD's holdings in Ascendis Pharma A/S were worth $1,377,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in the business. RA Capital Management L.P. increased its position in Ascendis Pharma A/S by 4.1% in the 4th quarter. RA Capital Management L.P. now owns 10,112,744 shares of the biotechnology company's stock valued at $1,392,221,000 after acquiring an additional 402,316 shares during the period. Avoro Capital Advisors LLC boosted its stake in Ascendis Pharma A/S by 2.3% during the 4th quarter. Avoro Capital Advisors LLC now owns 5,103,055 shares of the biotechnology company's stock valued at $702,538,000 after purchasing an additional 114,167 shares in the last quarter. Artisan Partners Limited Partnership boosted its stake in Ascendis Pharma A/S by 0.9% during the 4th quarter. Artisan Partners Limited Partnership now owns 4,450,420 shares of the biotechnology company's stock valued at $612,689,000 after purchasing an additional 39,309 shares in the last quarter. Janus Henderson Group PLC boosted its stake in Ascendis Pharma A/S by 4.6% during the 4th quarter. Janus Henderson Group PLC now owns 4,380,382 shares of the biotechnology company's stock valued at $602,910,000 after purchasing an additional 193,688 shares in the last quarter. Finally, Capital International Investors boosted its stake in Ascendis Pharma A/S by 35.7% during the 4th quarter. Capital International Investors now owns 2,863,249 shares of the biotechnology company's stock valued at $394,183,000 after purchasing an additional 753,859 shares in the last quarter.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the company. The Goldman Sachs Group increased their price target on Ascendis Pharma A/S from $200.00 to $225.00 and gave the company a "buy" rating in a research note on Thursday, February 13th. Wedbush increased their price target on Ascendis Pharma A/S from $181.00 to $212.00 and gave the company an "outperform" rating in a research note on Friday, May 2nd. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $200.00 price target on shares of Ascendis Pharma A/S in a research note on Monday, May 12th. JPMorgan Chase & Co. increased their price target on Ascendis Pharma A/S from $200.00 to $245.00 and gave the company an "overweight" rating in a research note on Friday, May 2nd. Finally, Morgan Stanley raised Ascendis Pharma A/S from an "equal weight" rating to an "overweight" rating and increased their price target for the company from $180.00 to $250.00 in a research note on Monday, May 5th. One investment analyst has rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. According to MarketBeat, Ascendis Pharma A/S currently has an average rating of "Moderate Buy" and a consensus target price of $216.07.

Ascendis Pharma A/S Stock Up 0.0%

Shares of Ascendis Pharma A/S stock traded up $0.06 during midday trading on Friday, hitting $157.60. The company's stock had a trading volume of 502,233 shares, compared to its average volume of 493,596. The firm has a market capitalization of $9.61 billion, a P/E ratio of -22.20 and a beta of 0.41. The stock has a 50-day simple moving average of $157.15 and a 200-day simple moving average of $142.50. Ascendis Pharma A/S has a 1-year low of $111.09 and a 1-year high of $183.00.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last issued its earnings results on Thursday, May 1st. The biotechnology company reported ($1.66) EPS for the quarter, missing the consensus estimate of ($1.56) by ($0.10). The firm had revenue of $123.97 million during the quarter, compared to analyst estimates of $98.56 million. As a group, sell-side analysts predict that Ascendis Pharma A/S will post -4.34 earnings per share for the current year.

Ascendis Pharma A/S Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.